Last reviewed · How we verify

NCT04947683: ALK

Patient Journey With Advanced Lung Cancer Positive for ALK Fusion in Brazil

Completed Last updated 2 August 2023
What this trial tests

trial in Carcinoma, Non-Small-Cell Lung in 101 participants. Completed in 3 March 2023.

Timeline
6 April 2020
Primary endpoint
14 February 2023
3 March 2023

Quick facts

Lead sponsorLatin American Cooperative Oncology Group
StatusCompleted
Study typeOBSERVATIONAL
Enrollment101
Start date6 April 2020
Primary completion14 February 2023
Estimated completion3 March 2023
Sites5 locations across Brazil

Conditions studied

Sponsor

Latin American Cooperative Oncology Group

Who can join

18 and older, any sex, with Carcinoma, Non-Small-Cell Lung. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Observational, retrospective cohort study that will include patients diagnosed with NSCLC and ALK rearrangement between January 2015 and December 2020.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Carcinoma, Non-Small-Cell Lung

Currently open trials in the same condition.

Other Latin American Cooperative Oncology Group trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04947683.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing